37 results about "Liposome Vesicle" patented technology

The invention belongs to the technical field of medicine, relates to a low-concentration PEG-lipid derivative and an application thereof, particularly to a prescription composition and an application thereof which can relieving or avoiding accelerated blood clearance (ABC) of PEGylation preparations. According to the low-concentration PEG-lipid derivative and the application thereof, the low-content PEG-lipid derivative is used for modifying liquid particle preparations such as emulsions, liposome, vesicles, micro emulsions, micelles and nano-particles, PEG and lipid chain segments are connected through ester bonds, amido bonds or ether bonds in the PEG-lipid derivative, and the molecular weight of the PEG is 200-20000 Dalton. Preparations prepared by the PEG-lipid derivative can only cause slight or cannot cause the ABC, namely, can reduce or avoid the ABC after repeated injection. The low-concentration PEG does not reduce in vitro anti-tumor activity of preparations, and stability of the preparation can be improved if the low-concentration PEG-lipid derivative is added, particularly shaking instability of antagonistic emulsions.

A power assisted method and injector device for controllably delivering to patients a dispersion medicament or diagnostically active agent, the homogeneity of which is preserved throughout delivery. Diagnostically active agents disclosed are gas microbubble suspensions useful in ultrasonic diagnostic imaging and liposomal formulations in which liposome vesicles are loaded with iodinated compounds.

The invention belongs to the technical field of medicaments, and provides application of a cleavable polyethylene glycol (PEG) lipid derivative to preparation of a PEGylated preparation for relieving or avoiding accelerated blood clearance. In the application, liquid microparticle preparations such as liposome, vesicles, emulsions, microemulsion, micelles, nanoparticles and the like are modified by the cleavable PEG lipid derivative such as PEG-cholesteryl hemisuccinate, PEG-cholesteryl methyl carbonate, PEG-alpha tocopheryl hemisuccinate and the like; and the measurement of variation of preparation elimination in tissues such as animal blood plasma, liver, spleen and the like after a cleavable PEG lipid derivative-modified medicinal preparation is repeatedly injected proves that repeated injection of cleavable PEG lipid derivative-modified microparticle preparations only causes light accelerated blood clearance or avoids the accelerated blood clearance, namely the accelerated blood clearance can be relieved or avoided. The invention discloses new application of the cleavable PEG lipid derivative.

This invention provides an aqueous / t-butanol solvent-system, facile reconstitute, submicron-reconsitiute preliposome-lyophilaye and method of its preparation and use.In one embodiment this entails a modified method for the preparation of a submicron and stable liposome formulation of the non-cross-resistant anthracycline Annamycin is described. The optimal lipid composition was DMPC:DMPG at a 7:3 molar ratio and the optimal lipid:drug weight ratio 50:1. The selected formulation is a preliposome lyophilized powder that contains the phospholipids, Annamycin, and 1.7 mg Tween 20 per mg of Annamycin. The liposome suspension is obtained on the day of use by adding normal saline at 37° C. (1 ml per mg Annamycin) and hand-shaking for one minute. The presence of Tween 20 is essential in shortening the reconstitution step (from >2 hours to 1 minute), avoiding the early formation of free drug crystals, and reducing the median particle size (from 1.5 μm to 0.15-0.20 μm) without destruction of the liposome vesicles. The chemical stability of the preliposome powder at room temperature was >3 months and the chemical and physical stability of the liposome suspension at room temperature >24 hours. The in vitro cytotoxicity of the formulation was equivalent to that prepared by the standard evaporation method. The results of the study indicate that small amounts of surfactant may be used to enhance the reconstitution step and reduce the liposome size of lyophilized liposome formulations of lipophilic drugs.

A power assisted method and injector device for controllably delivering to patients a dispersion medicament or diagnostically active agent, the homogeneity of which is preserved throughout delivery. Diagnostically active agents disclosed are gas microbubble suspensions useful in ultrasonic diagnostic imaging and liposomal formulations in which liposome vesicles are loaded with iodinated compounds.

A gummy includes an inner portion, a formulation having a dispersion including a plurality of liposomal vesicles contained in the inner portion; and an outer portion which surrounds the inner portion. The formulation includes an active ingredient including cannabidiol (CBD), phospholipid contained in the liposomal vesicles, and a optionally added coating material, the CBD being incorporated within the liposomal vesicles. A method of making such gummy having the CBD formulation in the inner portion thereof includes setting up a central filling apparatus having a shell syrup hopper, a central filling hopper, and a manifold branch and nozzle mechanism; filling the shell syrup hopper with the base material; filling the central filling hopper with the CBD formulation; dispensing the base material and CBD formulation in the manifold branch and nozzle mechanism, and further into the gummy mold; and extracting the gummy from the gummy mold.

A method of pereparing a rediographic contrast medium containing liposomes is disclosed, comprising (a) dissolving a phospholipid and a sterol in a supercritical or subcritical carbon dioxide in the presence of a compound containing a hydroxyl group or a polyalkyleneoxide group, (b) adding thereto an aqueous solution containing an iodine compound to form micelles and (c) discharging the carbon dioxide to form liposomal vesicles enclosing the iodine compound.

The present invention relates generally to methods and devices for the preparation of vesicles, including micelles, particularly liposomes, the method comprising extruding a solution containing a substance capable of forming vesicles through a mesh membrane under high pressure.

The invention provides sorafenib solid lipid nanoparticles and a preparation method thereof. A phospholipid film is used as a shell, sorafenib and indocyanine green are taken as cores, wherein liposoluble sorafenib is encapsulated in a hydrophobic region of the phospholipid bilayer, and hydrophilic indocyanine green is located in liposome vesicles formed by the phospholipid bilayer. The preparation method comprises the following steps: weighing sorafenib and phospholipid, adding an organic solvent for dissolution to obtain an organic phase, and then removing an organic solvent to obtain the phospholipid film containing sorafenib; weighing indocyanine green, and dissolving indocyanine green in deionized water to obtain a water phase; adding the obtained water phase to the obtained phospholipid film, stirring and mixing the solution uniformly, and performing squeezing and filtering to obtain the final product. According to the sorafenib solid lipid nanoparticles, sorafenib and indocyanine green are loaded into a phospholipid film nano carrier together, so that toxicity and solubility of sorafenib can be improved, and light resistance and tumor aggregation resistance of indocyanine green can be enhanced.

A method of pereparing a rediographic contrast medium containing liposomes is disclosed, comprising (a) dissolving a phospholipid and a sterol in a supercritical or subcritical carbon dioxide in the presence of a compound containing a hydroxyl group or a polyalkyleneoxide group, (b) adding thereto an aqueous solution containing an iodine compound to form micelles and (c) discharging the carbon dioxide to form liposomal vesicles enclosing the iodine compound.

The invention discloses the composition, preparation and application of a magnetic liposome vesicle, and belongs to the technical field of emulsifier preparation. The present invention adopts magnetic Fe 3 O 4 Nanoparticles induce self-assembly of conjugated linoleic acid (CLA) into magnetic vesicles, and then make CLA@Fe 3 O 4 Self-crosslinking of CLA molecules in bilayers yields stable SCLA@Fe 3 O 4 (Self-cross-linked conjugated linoleic acid) magnetic vesicles. The particle size of the prepared magnetic liposome vesicles does not exceed 25 nm, and can be used to prepare pH / magnetic dual-responsive Pickering emulsions, and the internal phase volume can be as high as 92%. The material used in the invention has good biocompatibility, simple process, easy-to-obtain raw materials, and easy control of particle size and shape.

A method of producing positively charged liposome vesicles for use as carriers of lipophilic molecules. A mixture of hydrogenated phospholipids, a cationic excipient and a lipophilic molecule are dissolved in a solvent to form a composition. The composition is dried to remove the solvent. The dried composition is hydrated to form liposome vesicles and optionally the liposome vesicles are homogenized to form smaller vesicles. The vesicles are useful for delivery lipophilic molecules, such as, but limited to, lutein and zeaxanthin, to ocular tissues using iontophoresis.

The invention belongs to the technical field of medicaments, and provides application of a cleavable polyethylene glycol (PEG) lipid derivative to preparation of a PEGylated preparation for relieving or avoiding accelerated blood clearance. In the application, liquid microparticle preparations such as liposome, vesicles, emulsions, microemulsion, micelles, nanoparticles and the like are modified by the cleavable PEG lipid derivative such as PEG-cholesteryl hemisuccinate, PEG-cholesteryl methyl carbonate, PEG-alpha tocopheryl hemisuccinate and the like; and the measurement of variation of preparation elimination in tissues such as animal blood plasma, liver, spleen and the like after a cleavable PEG lipid derivative-modified medicinal preparation is repeatedly injected proves that repeatedinjection of cleavable PEG lipid derivative-modified microparticle preparations only causes light accelerated blood clearance or avoids the accelerated blood clearance, namely the accelerated blood clearance can be relieved or avoided. The invention discloses new application of the cleavable PEG lipid derivative.

The invention relates to a lipidosome medical composition which uses momestasone furoate as an active component, and a cyst diameter of lipidosome is smaller than 800nm. The composition comprises 0.025 percent to 0.2 percent of momestasone furoate as the active component, 0.5 percent to 6 percent of phospholipid, 0 percent to 1 percent of lipophilic additive, 0.01 percent to 1 percent of antioxidant which is used for preserving the medical composition, a pH buffering agent which is used for retaining a pH value from 5 to 7.5, 3 percent to 15 percent of humectant, 20 percent to 30 percent of oil phrase component, 0.01 percent to 0.1 percent of antimicrobial preservative and the balanced of water. The momestasone furoate lipidosome cream is used for treating skin diseases of human beings oranimals.

A gummy includes an inner portion, a formulation having a dispersion including a plurality of liposomal vesicles contained in the inner portion; and an outer portion which surrounds the inner portion. The formulation includes an active ingredient including cannabidiol (CBD), phospholipid contained in the liposomal vesicles, and a optionally added coating material, the CBD being incorporated within the liposomal vesicles. A method of making such gummy having the CBD formulation in the inner portion thereof includes setting up a central filling apparatus having a shell syrup hopper, a central filling hopper, and a manifold branch and nozzle mechanism; filling the shell syrup hopper with the base material; filling the central filling hopper with the CBD formulation; dispensing the base material and CBD formulation in the manifold branch and nozzle mechanism, and further into the gummy mold; and extracting the gummy from the gummy mold.